Letrozole as a Treatment of Endometrial Cancer
Status
Conditions
Treatments
Details and patient eligibility
About
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
- Post menopausal status must be demonstrated
- Signed informed consent
Exclusion criteria
- FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
- Younger than 40 or postmenopausal status not established
- Pregnant or breastfeeding
Trial design
Primary purpose
Allocation
Interventional model
Masking
43 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal